Healthcare
•3759 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3759)
| Company | Market Cap | Price |
|---|---|---|
|
PSNL
Personalis, Inc.
NeXT Personal is a tumor-informed liquid biopsy-based MRD test, central to PSNL's offerings.
|
$950.62M |
$10.71
-4.46%
|
|
CDNA
CareDx, Inc
Directly provides Laboratory Testing & Advisory Services through its testing portfolio and diagnostic operations.
|
$947.97M |
$17.81
-0.50%
|
|
SPRY
ARS Pharmaceuticals, Inc.
Neffy uses a proprietary Drug Delivery Platform enabling intranasal delivery of epinephrine.
|
$945.77M |
$9.57
+3.18%
|
|
AVBP
ArriVent BioPharma, Inc. Common Stock
Company focuses on oncology therapeutics, positioning it within Biotech - Oncology.
|
$935.11M |
$23.07
+1.29%
|
|
MRVI
Maravai LifeSciences Holdings, Inc.
Maravai produces highly modified nucleic acids (mRNA, oligonucleotides) and related inputs, including acquisitions expanding DNA/RNA production capabilities.
|
$929.52M |
$3.65
-2.93%
|
|
PLSE
Pulse Biosciences, Inc.
Pulse Biosciences develops nsPFA-based medical devices (e.g., CellFX platform) for non-thermal tissue ablation across soft tissue and cardiac indications.
|
$927.77M |
$13.80
+3.53%
|
|
SVRA
Savara Inc.
Molgramostim is a recombinant GM-CSF protein delivered as an inhalation therapy; directly a recombinant protein/enzymes product.
|
$926.41M |
$5.37
+4.27%
|
|
FLGT
Fulgent Genetics, Inc.
Company operates clinical lab chains providing diagnostic testing.
|
$922.86M |
$30.16
-2.25%
|
|
MNMD
Mind Medicine (MindMed) Inc.
MindMed's pipeline centers on neuropsychiatric drug development, placing it in the Neuropsychiatric Drug Development investable theme.
|
$920.66M |
$12.10
+1.85%
|
|
ALNT
Allient Inc.
Medical Device Components align with Allient’s product capabilities used in medical device applications.
|
$917.51M |
$54.05
+1.37%
|
|
NTLA
Intellia Therapeutics, Inc.
Direct focus on CRISPR-based in vivo gene therapies (NTLA-2002 and nex-z) and a delivery platform, i.e., core gene-therapy biotech business.
|
$914.60M |
$8.53
-0.23%
|
|
RIGL
Rigel Pharmaceuticals, Inc.
Rigel's core products are oncology/hematology therapies (TAVALISSE, REZLIDHIA, GAVRETO), fitting Biotech - Oncology.
|
$914.09M |
$51.05
+3.01%
|
|
ARVN
Arvinas, Inc.
Lead program ARV-471 (vepdegestrant) is an oncology-focused asset, reflecting Arvinas' core business in cancer therapeutics and PROTAC technology.
|
$911.85M |
$12.41
+2.39%
|
|
MEG
Montrose Environmental Group, Inc.
Laboratory testing and advisory services as part of Montrose's measurement and analysis offerings.
|
$905.10M |
$25.66
+0.25%
|
|
ERAS
Erasca, Inc.
Erasa is a clinical-stage biotechnology company developing targeted cancer therapies, i.e., Biotech - Oncology.
|
$887.89M |
$3.13
+1.95%
|
|
VIR
Vir Biotechnology, Inc.
Vir is expanding a targeted oncology portfolio around masked T-cell engagers, placing it in Biotech - Oncology.
|
$887.68M |
$6.41
-0.47%
|
|
MLTX
MoonLake Immunotherapeutics
MoonLake focuses on immunology therapeutics with Sonelokimab (SLK) for inflammatory skin and joint diseases.
|
$886.38M |
$13.81
+1.47%
|
|
IOVA
Iovance Biotherapeutics, Inc.
Company's core offering is cell therapy (TIL) with autologous lymphocytes, including next-generation pipeline programs, defining the Biotech - Cell Therapy category.
|
$882.92M |
$2.44
-1.81%
|
|
LENZ
LENZ Therapeutics, Inc.
VIZZ is an aceclidine-based eye drop marketed as an ophthalmic drug for presbyopia.
|
$876.20M |
$30.67
+2.64%
|
|
RZLT
Rezolute, Inc.
Ersodetug is a human monoclonal antibody designed to treat HI by modulating insulin signaling, representing a monoclonal antibody therapeutic product.
|
$868.16M |
$9.54
+0.16%
|
|
ABUS
Arbutus Biopharma Corporation
Imdusiran is an RNA interference therapeutic (RNAi) targeting HBV, representing the core product category.
|
$845.39M |
$4.43
+2.55%
|
|
SIBN
SI-BONE, Inc.
SI-BONE operates as a medical device company that designs, develops and sells orthopedic implants and related medical devices.
|
$840.39M |
$19.49
-0.92%
|
|
ATAI
Atai Beckley N.V
Acquisition of IntelGenx adds drug delivery platforms (oral thin-film) powering VLS-01 and related assets.
|
$803.77M |
$3.75
-0.27%
|
|
ESPR
Esperion Therapeutics, Inc.
Directly sells/markets cardiovascular drugs (NEXLETOL, NEXLIZET).
|
$796.41M |
$3.96
+7.18%
|
|
ALMS
Alumis Inc. Common Stock
Alumis is developing oral TYK2 inhibitors (ESK-001 and A-005), a major product category of oral small molecule therapeutics.
|
$795.05M |
$7.65
+4.37%
|
|
OCS
Oculis Holding AG
Direct ophthalmic drug products (OCS-01, OCS-02, OCS-05) are the core offerings: ophthalmic drugs.
|
$793.18M |
$18.92
-2.12%
|
|
REPL
Replimune Group, Inc.
Replimune is oncology-focused biotech developing oncolytic immunotherapies.
|
$785.24M |
$10.07
+5.67%
|
|
BFLY
Butterfly Network, Inc.
Core ultrasound imaging hardware and point-of-care devices (POCUS) produced by Butterfly.
|
$775.36M |
$3.08
-9.29%
|
|
GHRS
GH Research PLC
GH Research's focus on neuropsychiatric drug development (CNS/psychiatric disorders) via 5-MeO-DMT therapies.
|
$767.42M |
$14.75
-0.97%
|
|
MATW
Matthews International Corporation
Memorialization segment includes embalming chemicals and funeral supplies (memorialization products).
|
$767.31M |
$24.93
-1.01%
|
Showing page 15 of 38 (3759 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
